Biotech & Early Engagement Considerations: What Companies Must Consider When Developing an Asset

Emerging biotech companies are a significant and burgeoning sector of the pharmaceutical development market. These companies may require unique and specialized expertise to guide them through asset development. There are a multitude of considerations when evaluating an asset for development, including the vision for the asset, development and continuum capabilities, and global versus local development. 

In this whitepaper, you will learn: 

• How to navigate the complexities of asset development
• Overall considerations emerging biotech companies can be discussing with development partners
• What makes a successful partner who can assist a small biotech company with necessary development strategies

This is the first in a series of white papers that will help outline considerations for asset development. Lead the pack in all steps of the development process with this guide.

Xconomy

2 International Place #2610

Boston, MA 02110-4104

DOWNLOAD NOW: